Skip to main content

Table 3 Characteristics of patients with clinical cardiotoxicity

From: Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation

Patient

Clinical manifestation of cardiotoxicity

Day after HSCT

Baseline NT-proBNP/hs-cTnT

NT-proBNP/hs-cTnT

Conditioning regimen

CD ANT (mg/m2)

1

Chest pain, dyspnea

3

237/normal

9589/0,032

TBI + CY

390

2

Chest pain, dyspnea

1

320/normal

12 156/0,076

FLAMSA

125

3

Fluid retention, pericarditis

15

327/normal

3761/0,016

TBI + CY

150

4

Fluid retention

10

412/0,025

4817/

0,047

BUCY2

470

5

Cardiogenic shock

176

63,88/0,018

31 444/0,05

TBI + CY

150

  1. ANT anthracyclines, CY cyclophosphamide, hs-cTnT high sensitive cardiac troponin T, NT-proBNP N-terminal pro-B-type natriuretic peptide, TBI total body irradiation, CD cumulative dose, FLAMSA fludarabine + cytosine arabinosid + TBI + CY + amsacrine was replaced by idarubicin, BU busulphan